Cardlytics (NASDAQ: CDLX) Chief Executive Officer Amit Gupta has executed a substantial liquidation of company equity, offloading shares worth approximately $70,916 in early July. The sales, documented in a recent SEC filing, occurred on July 2 and July 6, following the vesting of restricted stock units (RSUs). This insider activity unfolds as Cardlytics shares trade at $4.37, a level hovering dangerously close to its 52-week low of $4.25. The stock has experienced a sharp decline, dropping more than 10% over the past week alone, reflecting heightened market scrutiny.
On July 2, Gupta disposed of 6,498 shares at a weighted average price of $4.395 per share. These transactions were executed at various price points ranging from $4.260 to $4.540. Four days later, on July 6, an additional 9,640 shares were sold at a weighted average price of $4.394 per share, with individual transaction prices falling between $4.280 and $4.510. The combined sales volume reached 16,138 shares, totaling approximately $70,916.
The sales were triggered by the acquisition of common stock through RSU vesting events. On July 1, Gupta acquired a total of 31,250 shares of common stock. These shares originated from two distinct RSU awards. The first tranche, comprising 12,500 shares, stemmed from an award that vested 50% on April 1, 2026, with the remaining 50% scheduled to vest in equal quarterly installments over a one-year period through April 1, 2027. This vesting is contingent upon Gupta remaining employed by the issuer on the respective vesting dates. The second tranche, consisting of 18,750 shares, derives from an RSU award set to vest in equal quarterly amounts over a two-year period through April 1, 2028, also subject to continued employment.
It is critical to note that effective June 5, 2026, Cardlytics implemented a 1-for-10 reverse stock split of its common stock. Consequently, the number of securities reported in the filing has been adjusted to accurately reflect this corporate action. With the company's market capitalization standing at a modest $25.61 million and earnings results due in 29 days, the stock remains a focal point for valuation analysis. According to InvestingPro analysis, Cardlytics appears undervalued at current levels, placing it among stocks on the most undervalued list.
In other recent developments, Cardlytics Inc. reported its first-quarter earnings for 2026, revealing an earnings per share (EPS) of -$0.11. This result surpassed analysts' expectations, which had projected an EPS of -$0.26, representing a positive EPS surprise of 57.69%. However, the company experienced a significant revenue shortfall, with actual revenue reported at $34.3 million compared to the anticipated $48.7 million. This represented a negative revenue surprise of -29.57%.
Analysts from various firms have been closely monitoring these developments. There have been no recent updates on any mergers or acquisitions involving Cardlytics. Additionally, there have been no recent reports of any analyst upgrades or downgrades for the company. These developments continue to be of interest to investors and analysts alike.